For example, Tyrosine kinase inhibitors (TKIs) targeting sensitizing mutations in the epidermal growth factor receptor (EGFR) gene constitute a vital cornerstone of non-small cell lung cancer management. Here, EGFR is linked to non-small cell lung carcinoma.